FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3118561678> ?p ?o ?g. }

• W3118561678 endingPage "600" @default.
• W3118561678 startingPage "592" @default.
• W3118561678 abstract "Tenofovir alafenamide (TAF) has been available in China for a short time, little is known about its safety and efficacy in patients with hepatitis B virus (HBV)–related acute-on-chronic liver failure (HBV-ACLF). We conducted this study to further verify the safety and efficacy of TAF in these patients. Eighty-eight eligible subjects were included and divided into three groups: TAF group, TDF group and ETV group. Clinical and laboratory test results were collected and the survival status, virus suppression status and liver and renal function improvement were observed during follow-up. No drug-related adverse events were observed within a 48-week observation period. At week 48, the survival rates of the three groups were 56.5%, 78.3% and 59.5% (p = 0.262). HBV DNA undetectable rates were similar (80.0% vs.75.0% vs.84.6%, respectively, p = 0.863). Liver function improved in all the three groups over time. Compared with the other two groups, patients in the TAF group had a greater decrease in serum creatinine (CR) and an increase in estimated glomerular filtration rate (eGFR), especially at week 12. At week 48, the median changes of CR were −0.7 (IQR −3.0, 13.0) vs. 15.0 (IQR −3.0, 21.0) vs. 5.0 (IQR −9.0, 14.0), respectively (p = 0.334), while the median changes of eGFR were −2.12 (IQR −13.87, 1.44) vs. −10.43 (IQR −20.21, 3.18) vs. −5.31 (IQR −14.72, 5.44) ml/min/1.73 m2, respectively (p = 0.592). In this real-world clinical study, TAF is as effective as TDF and ETV, and may be more beneficial in protecting renal function in the early stages of antiviral therapy." @default.
• W3118561678 created "2021-01-18" @default.
• W3118561678 creator A5001890971 @default.
• W3118561678 creator A5002852902 @default.
• W3118561678 creator A5008857498 @default.
• W3118561678 creator A5010503192 @default.
• W3118561678 creator A5014873304 @default.
• W3118561678 creator A5031514811 @default.
• W3118561678 creator A5068301817 @default.
• W3118561678 creator A5071494660 @default.
• W3118561678 creator A5078479753 @default.
• W3118561678 date "2021-01-19" @default.
• W3118561678 modified "2023-10-14" @default.
• W3118561678 title "The 48‐week safety and therapeutic effects of tenofovir alafenamide in hbv‐related acute‐on‐chronic liver failure: A prospective cohort study" @default.
• W3118561678 cites W1976104517 @default.
• W3118561678 cites W1991551165 @default.
• W3118561678 cites W2101870482 @default.
• W3118561678 cites W2150353364 @default.
• W3118561678 cites W2155223127 @default.
• W3118561678 cites W2162322495 @default.
• W3118561678 cites W2254417733 @default.
• W3118561678 cites W2521726183 @default.
• W3118561678 cites W2605785536 @default.
• W3118561678 cites W2755186880 @default.
• W3118561678 cites W2782856081 @default.
• W3118561678 cites W2791839818 @default.
• W3118561678 cites W2793190869 @default.
• W3118561678 cites W2793229999 @default.
• W3118561678 cites W2891971495 @default.
• W3118561678 cites W4211190027 @default.
• W3118561678 cites W4239743462 @default.
• W3118561678 cites W577533421 @default.
• W3118561678 doi "https://doi.org/10.1111/jvh.13468" @default.
• W3118561678 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33423348" @default.
• W3118561678 hasPublicationYear "2021" @default.
• W3118561678 type Work @default.
• W3118561678 sameAs 3118561678 @default.
• W3118561678 citedByCount "5" @default.
• W3118561678 countsByYear W31185616782021 @default.
• W3118561678 countsByYear W31185616782022 @default.
• W3118561678 countsByYear W31185616782023 @default.
• W3118561678 crossrefType "journal-article" @default.
• W3118561678 hasAuthorship W3118561678A5001890971 @default.
• W3118561678 hasAuthorship W3118561678A5002852902 @default.
• W3118561678 hasAuthorship W3118561678A5008857498 @default.
• W3118561678 hasAuthorship W3118561678A5010503192 @default.
• W3118561678 hasAuthorship W3118561678A5014873304 @default.
• W3118561678 hasAuthorship W3118561678A5031514811 @default.
• W3118561678 hasAuthorship W3118561678A5068301817 @default.
• W3118561678 hasAuthorship W3118561678A5071494660 @default.
• W3118561678 hasAuthorship W3118561678A5078479753 @default.
• W3118561678 hasConcept C126322002 @default.
• W3118561678 hasConcept C142462285 @default.
• W3118561678 hasConcept C159641895 @default.
• W3118561678 hasConcept C188816634 @default.
• W3118561678 hasConcept C197934379 @default.
• W3118561678 hasConcept C203014093 @default.
• W3118561678 hasConcept C2522874641 @default.
• W3118561678 hasConcept C2777382497 @default.
• W3118561678 hasConcept C2780306776 @default.
• W3118561678 hasConcept C2780593183 @default.
• W3118561678 hasConcept C2911190787 @default.
• W3118561678 hasConcept C2992208098 @default.
• W3118561678 hasConcept C2993143319 @default.
• W3118561678 hasConcept C3013748606 @default.
• W3118561678 hasConcept C71924100 @default.
• W3118561678 hasConcept C90924648 @default.
• W3118561678 hasConceptScore W3118561678C126322002 @default.
• W3118561678 hasConceptScore W3118561678C142462285 @default.
• W3118561678 hasConceptScore W3118561678C159641895 @default.
• W3118561678 hasConceptScore W3118561678C188816634 @default.
• W3118561678 hasConceptScore W3118561678C197934379 @default.
• W3118561678 hasConceptScore W3118561678C203014093 @default.
• W3118561678 hasConceptScore W3118561678C2522874641 @default.
• W3118561678 hasConceptScore W3118561678C2777382497 @default.
• W3118561678 hasConceptScore W3118561678C2780306776 @default.
• W3118561678 hasConceptScore W3118561678C2780593183 @default.
• W3118561678 hasConceptScore W3118561678C2911190787 @default.
• W3118561678 hasConceptScore W3118561678C2992208098 @default.
• W3118561678 hasConceptScore W3118561678C2993143319 @default.
• W3118561678 hasConceptScore W3118561678C3013748606 @default.
• W3118561678 hasConceptScore W3118561678C71924100 @default.
• W3118561678 hasConceptScore W3118561678C90924648 @default.
• W3118561678 hasIssue "4" @default.
• W3118561678 hasLocation W31185616781 @default.
• W3118561678 hasOpenAccess W3118561678 @default.
• W3118561678 hasPrimaryLocation W31185616781 @default.
• W3118561678 hasRelatedWork W1967427303 @default.
• W3118561678 hasRelatedWork W2061952790 @default.
• W3118561678 hasRelatedWork W2091254812 @default.
• W3118561678 hasRelatedWork W2319627057 @default.
• W3118561678 hasRelatedWork W2921896583 @default.
• W3118561678 hasRelatedWork W3110725543 @default.
• W3118561678 hasRelatedWork W3139139960 @default.
• W3118561678 hasRelatedWork W4225370543 @default.
• W3118561678 hasRelatedWork W4234861586 @default.
• W3118561678 hasRelatedWork W4360611280 @default.
• W3118561678 hasVolume "28" @default.

• next